Home
RGEN
RGEN News

Latest Repligen Corporation (RGEN) News on September 6, 2025

Argus Research

2 months ago

RGEN: Raising target price to $99.00

5 Insightful Analyst Questions From Repligen’s Q1 Earnings Call

StockStory

2 months ago

5 Insightful Analyst Questions From Repligen’s Q1 Earnings Call

Argus Research

3 months ago

RGEN: Raising target price to $140.00

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

StockStory

3 months ago

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

Three Stocks That May Be Trading Below Their Intrinsic Value In June 2025

Simply Wall St.

3 months ago

Three Stocks That May Be Trading Below Their Intrinsic Value In June 2025

Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks

StockStory

3 months ago

Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks

Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers

StockStory

3 months ago

Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers

Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?

Zacks

3 months ago

Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?

3 of Wall Street’s Favorite Stocks in Hot Water

StockStory

3 months ago

3 of Wall Street’s Favorite Stocks in Hot Water

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Zacks

3 months ago

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report

GlobeNewswire

3 months ago

Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report

Repligen Corporation to Present at William Blair Growth Conference

GlobeNewswire

3 months ago

Repligen Corporation to Present at William Blair Growth Conference

MT Newswires

4 months ago

Repligen Insider Sold Shares Worth $3,271,688, According to a Recent SEC Filing

Argus Research

4 months ago

RGEN: Raising target price to $138.00

Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know

StockStory

4 months ago

Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know

1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

StockStory

4 months ago

1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

Repligen Corporation to Present at Upcoming May Investor Conferences

GlobeNewswire

4 months ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Argus Research

4 months ago

RGEN: Lowering target price to $137.00

QGEN or RGEN: Which Is the Better Value Stock Right Now?

Zacks

4 months ago

QGEN or RGEN: Which Is the Better Value Stock Right Now?

Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare

Insider Monkey

4 months ago

Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

Insider Monkey

4 months ago

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’

Insider Monkey

4 months ago

Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’

RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

StockStory

4 months ago

RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

Morningstar Research

4 months ago

Analyst Report: Repligen Corporation

Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

Zacks

4 months ago

Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

MT Newswires

4 months ago

RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating

Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

4 months ago

Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Repligen Corp Earnings Call

MT Newswires

4 months ago

Wolfe Research Upgrades Repligen to Outperform From Peerperform

Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

Zacks

4 months ago

Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

StockStory

4 months ago

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

StockStory

4 months ago

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

MT Newswires

4 months ago

Repligen's Q1 Adjusted Earnings, Revenue Rise; Trims 2025 Adjusted Earnings, Raises Revenue Guidance

Associated Press Finance

4 months ago

Repligen: Q1 Earnings Snapshot

Repligen Reports First Quarter 2025 Financial Results

GlobeNewswire

4 months ago

Repligen Reports First Quarter 2025 Financial Results

What To Expect From Repligen Corp (RGEN) Q1 2025 Earnings

GuruFocus.com

4 months ago

What To Expect From Repligen Corp (RGEN) Q1 2025 Earnings

Repligen (RGEN) Q1 Earnings: What To Expect

StockStory

4 months ago

Repligen (RGEN) Q1 Earnings: What To Expect

3 Healthcare Stocks That Concern Us

StockStory

4 months ago

3 Healthcare Stocks That Concern Us

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Zacks

4 months ago

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline

Zacks

4 months ago

Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline

Argus Research

4 months ago

RGEN: Rating decreased to a SELL

Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

4 months ago

Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth

Three Stocks That May Be Undervalued In April 2025

Simply Wall St.

5 months ago

Three Stocks That May Be Undervalued In April 2025

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Zacks

5 months ago

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Argus Research

5 months ago

RGEN: Raising target price to $133.00

Repligen to Report First Quarter 2025 Financial Results

GlobeNewswire

5 months ago

Repligen to Report First Quarter 2025 Financial Results

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

StockStory

5 months ago

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

Argus Research

5 months ago

RGEN: Lowering target price to $114.00

Repligen Appoints Jacob Johnson As Vice President Investor Relations

GlobeNewswire

5 months ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

MT Newswires

5 months ago

RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Zacks

5 months ago

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Argus Research

5 months ago

RGEN: Lowering target price to $135.00

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

StockStory

5 months ago

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

Argus Research

5 months ago

RGEN: Lowering target price to $149.00

Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

Insider Monkey

5 months ago

Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

StockStory

6 months ago

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Zacks

6 months ago

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

MT Newswires

6 months ago

Evercore ISI Initiates Repligen at In Line With $155 Price Target

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

StockStory

6 months ago

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

StockStory

6 months ago

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

StockStory

6 months ago

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

Morningstar Research

6 months ago

Analyst Report: Repligen Corporation

3 Small-Cap Stocks Skating on Thin Ice

StockStory

6 months ago

3 Small-Cap Stocks Skating on Thin Ice

Thomson Reuters StreetEvents

6 months ago

Q4 2024 908 Devices Inc. Earnings Call

Argus Research

6 months ago

RGEN: Lowering target price to $163.00

MT Newswires

6 months ago

Top Midday Gainers

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Benzinga

6 months ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MT Newswires

6 months ago

Repligen Buys 908 Devices' Desktop Portfolio for $70 Million

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

GlobeNewswire

6 months ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Argus Research

6 months ago

RGEN: Raising target price to $170.00

Morningstar Research

6 months ago

Analyst Report: Repligen Corporation

Repligen's Q4 Earnings Beat Estimates, Revenues In Line

Zacks

6 months ago

Repligen's Q4 Earnings Beat Estimates, Revenues In Line

MT Newswires

6 months ago

RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating

MT Newswires

7 months ago

Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating

Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

7 months ago

Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Repligen Corp Earnings Call

Morningstar Research

7 months ago

Analyst Report: Repligen Corporation

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Benzinga

7 months ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

February 2025's US Stocks That May Be Trading Below Fair Value

Simply Wall St.

7 months ago

February 2025's US Stocks That May Be Trading Below Fair Value

What To Expect From Repligen Corp (RGEN) Q4 2024 Earnings

GuruFocus.com

7 months ago

What To Expect From Repligen Corp (RGEN) Q4 2024 Earnings

Repligen (RGEN) Beats Q4 Earnings Estimates

Zacks

7 months ago

Repligen (RGEN) Beats Q4 Earnings Estimates

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

StockStory

7 months ago

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

Associated Press Finance

7 months ago

Repligen: Q4 Earnings Snapshot

MT Newswires

7 months ago

Repligen Q4 Adjusted Earnings Decline, Revenue Increases -- Shares Up Pre-Bell

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

7 months ago

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

StockStory

7 months ago

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share Price

Simply Wall St.

7 months ago

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share Price

Morningstar Research

7 months ago

Analyst Report: Repligen Corporation

3 Healthcare Stocks Skating on Thin Ice

StockStory

7 months ago

3 Healthcare Stocks Skating on Thin Ice

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

7 months ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

MT Newswires

7 months ago

TD Cowen Initiates Repligen at Buy With $200 Price Target

Argus Research

7 months ago

RGEN: Rating increased to a HOLD

MT Newswires

7 months ago

RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating

HRMY vs. RGEN: Which Stock Is the Better Value Option?

Zacks

7 months ago

HRMY vs. RGEN: Which Stock Is the Better Value Option?

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Zacks

7 months ago

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Argus Research

7 months ago

RGEN: Raising target price to $147.00

Argus Research

7 months ago

RGEN: Raising target price to $144.00

Argus Research

8 months ago

RGEN: Raising target price to $139.00

HRMY or RGEN: Which Is the Better Value Stock Right Now?

Zacks

8 months ago

HRMY or RGEN: Which Is the Better Value Stock Right Now?

Morningstar Research

8 months ago

Analyst Report: Repligen Corporation

Share on Social Networks: